CAR-T therapies carry meaningful safety risks, and toxicity is known to vary with factors including disease characteristics, patient factors and the therapy its...
Continue reading
In genetic medicine, we increasingly know what to deliver. The unsolved problem is getting it to the right place in the body. That was the central thesis in the...
Continue reading
On 29 July 29, 2026, the same clinical trial data produced opposite verdicts. The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that a...
Continue reading
A genetically-defined trial can be designed correctly and still stall. The protocol names the right molecular subtype, the endpoints are sound, and the therapeu...
Continue reading
Precision medicine clinical trials are designed by some of the most capable scientists in drug development. The biomarker hypotheses are well-reasoned, the endp...
Continue reading
On July 20, 2026, Mayo Clinic reported peer-reviewed evidence that decentralization changes who takes part in clinical research. In a study published in JAMA Ne...
Continue reading
Most people with inflammatory bowel disease do not carry one broken gene. They carry risk spread across many genes and regulatory regions at once, which is why ...
Continue reading
On 20 July 2026, The New York Times reported that the genetic risk tools entering clinical use do not perform equally well across populations. Polygenic risk sc...
Continue reading
Most people accumulate cancer-associated blood mutations as they age, and quietly, without ever developing cancer. A growing body of evidence now links those mu...
Continue reading
For decades, the dominant framework for understanding neurodegenerative disease has centered on inherited risk genes. A growing body of single-cell genomics res...
Continue reading